Drug
Lisaftoclax clinical trials
Also written APG-2575.
- studies test it
- 31
- open now
- 27
- in phase 3
- 8
- first study started
- 2018
Keep track of what changes. Save the Lisaftoclax studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
31 studies that test it; most in 2026 (12)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 11
- Phase 2
- 17
- Phase 3
- 8
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 16
Ascentage Pharma Group Inc. (15) · Institute of Hematology & Blood Diseases Hospital, China (4) · First Affiliated Hospital of Zhejiang University (2) · Henan Cancer Hospital (2) · Guangdong Second Provincial General Hospital (1) · LanZhou University (1) · Peking University First Hospital (1) · The Affiliated People's Hospital of Ningbo University (1)
Often tested with
Tested in the same studies.
Homoharringtonine (4) · Azacitidine (4) · Rituximab (4) · Daunorubicin (3) · Cytarabine (3) · Pirtobrutinib (3) · Aclarubicin (2) · Mitoxantrone (2)
Studies
Open first, then newest update. How each study uses Lisaftoclax is read from its arms, and is right about nine times in ten.
Testing it · 31
- Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).RecruitingPhase 3Ascentage Pharma Group Inc.NCT06641414Written as Lisaftoclax (APG-2575)
- Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07831395Written as Lisaftoclax (APG-2575)
- Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy FailureEnrolling by invitationPhase 2Guangdong Second Provincial General HospitalNCT07813390Written as Lisaftoclax (APG-2575)
- A Single-center, Prospective, Exploratory Clinical StudyNot yet recruitingNot applicableLanZhou UniversityNCT07795099Written as Lisaftoclax
- Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT05495035Written as Olverembatinib, APG-2575, Dexamethasone
- APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT05701306Written as APG-2575
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06265545Written as Lisaftoclax
- Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell LymphomaNot yet recruitingPhase 2Henan Cancer HospitalNCT07459608Written as Lisaftoclax
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingPhase 3Ascentage Pharma Group Inc.NCT06319456Written as Lisaftoclax (APG-2575)
- Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRecruitingPhase 2Ruijin HospitalNCT07272499Written as Lisaftoclax (APG-2575)
- Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)Not yet recruitingPhase 2Peking University First HospitalNCT07717580Written as Lisaftoclax (APG-2575)
- Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of RelapseNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07686965Written as Lisaftoclax Plus Azacitidine
- Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted TherapyNot yet recruitingPhase 2Henan Cancer HospitalNCT07684950Written as Lisaftoclax
- Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsNot yet recruitingPhase 2/3The Affiliated People's Hospital of Ningbo UniversityNCT07597941Written as Lisaftoclax (APG-2575)
- Global Trial in APG2575 for Patients With CLL/SLLRecruitingPhase 3Ascentage Pharma Group Inc.NCT06104566Written as lisaftoclax +BTK inhibitor
- Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651163Written as Lisaftoclax+daunorubicin+cytarabine
- Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651176Written as Lisaftoclax+daunorubicin+cytarabine
- Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07601607Written as Lisaftoclax
- Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLRecruitingPhase 2Ascentage Pharma Group Inc.NCT05147467Written as APG2575
- A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.RecruitingPhase 1/2Ascentage Pharma Group Inc.NCT06182969Written as APG-2575
See all 31 studies that test Lisaftoclax →
Given in every arm · 5 — Lisaftoclax is usual care beside what is tested
- Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT04501120Written as Lisaftoclax (APG-2575)
- Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II StudyNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07398638Written as Lisaftoclax
- Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT04494503Written as APG-2575
- A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast CancerSuspendedPhase 1/2Ascentage Pharma Group Inc.NCT04946864Written as APG-2575
- APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownPhase 1/2Ascentage Pharma Group Inc.NCT04674514Written as APG-2575
Codes
What other systems call Lisaftoclax · ClinicalTrials.gg INT002005
- MeSH (NLM) C000726452LisaftoclaxOne source ClinicalTrials.gov
- UNII (FDA) OSL3FEZ1IFLISAFTOCLAXConfirmed FDA, Wikidata
- Wikidata Q124721221lisaftoclaxConfirmed FDA, Wikidata
- NCI Thesaurus C156249LisaftoclaxOne source FDA
- DrugBank DB18054One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000726452 | Lisaftoclax | One source ClinicalTrials.gov |
| UNII (FDA) | OSL3FEZ1IF | LISAFTOCLAX | Confirmed FDA, Wikidata |
| Wikidata | Q124721221 | lisaftoclax | Confirmed FDA, Wikidata |
| NCI Thesaurus | C156249 | Lisaftoclax | One source FDA |
| DrugBank | DB18054 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.